BENIGN UTERINE TUMOUR- UTERINE FIBROIDS
Conditions
Interventions
Intravenous Tranexamic acid
Sponsors
Dr. John Oluwadamilola OJO
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women diagnosed of uterine fibroid and scheduled for abdominal myomectomy No previous history of myomectomy or pelvic surgery No chronic medical disorder such as diabetes, hypertension, pulmonary or cardiac diseases No previous history of allergy or adverse drug reaction to misoprostol or tranexamic acid (TXA)
Exclusion criteria
Exclusion criteria: Non-consenting eligible patient with uterine fibroid scheduled for myomectomy Patients with medical disorders like hypertension, diabetes, pulmonary or cardiac disorder Allergic to misoprostol or tranexamic acid Previous myomectomy or pelvic surgery Patient receiving preoperative hormonal therapy: example GnRH analogues Haemoglobin less than 10mg/dl Pregnancy Adenomyosis History of bleeding disorder or coagulopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraoperative estimated blood loss (EBL) will be measured using both gravimetric and volumetric method | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the haematocrit (Hct) from preoperative baseline to 24hours post-operative Need for blood transfusion: number of patients receiving intra-operative or postoperative transfusion and the total units of blood transfused per patient Operative time: from skin incision to closure of the skin (mins) Length of hospital stay Adverse drug reaction vis-à-vis nausea, vomiting,diarrhoea, fever, chills and rigor, thromboembolic event, allergic reaction and seizure | — |
Countries
Nigeria
Contacts
Public ContactDANIEL ADEKANLE
PROFESSOR
Outcome results
None listed